https://scholars.lib.ntu.edu.tw/handle/123456789/539864
標題: | Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan | 作者: | CHUN-YI LU Chung C.-H. LI-MIN HUANG Kruger E. Tan S.-C. Zhang X.-H. Chiu N.-C. |
公開日期: | 2020 | 出版社: | BioMed Central Ltd | 卷: | 18 | 期: | 1 | 起(迄)頁: | 30 | 來源出版物: | Cost Effectiveness and Resource Allocation | 摘要: | Background: Streptococcus pneumoniae (S. pneumoniae) and non-typeable Haemophilus influenzae (NTHi) are substantial contributors to morbidity and mortality of diseases including invasive pneumococcal diseases (IPDs), pneumonia and acute otitis media (AOM) worldwide. In Taiwan, 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine (PHiD-CV) and 13-valent pneumococcal conjugate vaccine (PCV13) are licensed in children against pneumococcal disease. In addition to S. pneumoniae, clinical trials suggest efficacy of PHiD-CV against NTHi AOM. This study aims at evaluating the cost-effectiveness of a 2 + 1 schedule of PHiD-CV vs. PCV13 2 + 1 in the universal mass vaccination program of infants in Taiwan. Methods: A published Markov cohort model was adapted to simulate the epidemiological burden of IPD, pneumonia and AOM for a birth cohort in Taiwan over 10 years. The probability of entering a specific health state was based on the incidence rate of the diseases. Only direct medical costs were included, and costs and outcomes were discounted annually. Vaccine efficacy assumptions were based on published data and validated by a panel of independent experts. Clinical, epidemiological, and serotype distribution data were based on locally published data or the National Health Insurance Research Database. Price parity of vaccines was assumed. Published pneumococcal disease-related disutility weights were used due to lack of local data. Incremental cost-effectiveness ratio was calculated and benchmarked against the recommended threshold in Taiwan. Extensive one-way sensitivity analysis, alternative scenarios and probabilistic sensitivity analysis were performed to test the robustness of the results. Results: PHiD-CV would potentially reduce the number of NTHi-related AOM cases substantially and prevent comparable IPD and pneumonia-related cases and deaths compared to PCV13. Over a 10-year horizon, PHiD-CV is estimated to dominate PCV13, saving 6.7 million New Taiwan Dollars (NTD) and saving 21 quality-adjusted life years. The result was robust over a wide range of sensitivity analyses. The dominance of PHiD-CV was demonstrated in 90.5% of the simulations. Conclusions: PHiD-CV 2 + 1 would provide comparable prevention of IPD, pneumonia cases and additional reduction of NTHi-AOM cases, and is considered dominant compared with PCV13 2 + 1 in Taiwan. ? 2020 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092507401&doi=10.1186%2fs12962-020-00225-9&partnerID=40&md5=8ed7cd1df2927e162d51921d49559408 https://scholars.lib.ntu.edu.tw/handle/123456789/539864 |
ISSN: | 1478-7547 | DOI: | 10.1186/s12962-020-00225-9 | SDG/關鍵字: | 10 valent pneumococcal non typeable Haemophilus influenzae protein D conjugate vaccine; bacterial vaccine; Pneumococcus vaccine; unclassified drug; acute otitis media; adolescent; adult; Article; child; cohort analysis; controlled study; cost control; cost effectiveness analysis; cost utility analysis; disease burden; drug cost; drug dose regimen; drug efficacy; health care cost; health program; human; major clinical study; Markov chain; mass immunization; mortality; outcome assessment; pneumococcal infection; pneumonia; quality adjusted life year; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。